4 marzo 2021 – EMA announced that it has started evaluating an application to extend the use of a medicine called Veklury (remdesivir). Veklury is currently authorized for use in adults and adolescents with pneumonia requiring supplemental oxygen and was first authorized in the EU in July 2020. The active substance, remdesivir, is a viral RNA polymerase inhibitor that interferes with the production of viral RNA (genetic material), preventing the SARS-CoV-2 virus from multiplying inside cells. The result of the evaluation is expected before the summer. This opinion will be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

For more information, see here.